Raymond James analyst Gary Nachman raised the firm’s price target on ADMA Biologics to $6 from $5 and keeps a Strong Buy rating on the shares. ADMA delivered a solid beat and raise quarter for Q2, supporting the firm’s thesis that this is an improving numbers story, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ADMA:
- ADMA Biologics price target raised to $7 from $6 at Mizuho
- ADMA Biologics price target raised to $5 from $4.50 at H.C. Wainwright
- ADMA Earnings this Week: How Will it Perform?
- ADMA Biologics to Report Second Quarter 2023 Financial Results on August 9, 2023
- ‘Load Up,’ Says Raymond James About These 2 ‘Strong Buy’ Stocks